Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Early VA gain predictive of visual response after dexamethasone treatment
Healio
The 24-month, retrospective, multinational study included 155 eyes with macular edema secondary to either central retinal vein occlusion (CRVO, 65 eyes) or branch retinal vein occlusion (BRVO, 90 eyes). The eyes were treated with dexamethasone implant ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Retinal Vein Occlusion Market Analysis Revealing Key Drivers & Growth Trends through 2023
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment and end user. On the basis the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis of ...

and more »

Find Market Research By Abhishek Budholiya (press release) (blog)

Retinal Vein Occlusion Therapeutics Market to Hold a High Potential for Growth by 2021
Find Market Research By Abhishek Budholiya (press release) (blog)
The RVO is mainly of two types based on the anatomy of the vein occlusion. The two types are branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The BRVO occurs when the vein in the distal retinal system gets occluded ...


Marea Informative

Regeneron Pharmaceuticals Inc (REGN) Holdings Decreased by Opus Point Partners Management LLC
Macon Daily
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals (NASDAQ:REGN) Earning Somewhat ...StockNewsTimes
Regeneron Pharmaceuticals (REGN) Earns Daily News Sentiment ...Marea Informative (blog)

all 15 news articles »

StockNewsTimes

$1.58 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Zoetis teams up with Regeneron to discover new vet treatmentsSeeking Alpha
Kiniksa Pharmaceuticals IPO: Cash KingSeeking Alpha
StreetInsider.com
all 111 news articles »

Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each sufferer. There are some cases where a person can recover from BRVO. Here we look at the ...


Regeneron Pharmaceuticals Inc (REGN) Shares Sold by California State Teachers Retirement System
RealistInvestor.com
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Regeneron Pharmaceuticals (REGN) Upgraded at BidaskClub
The Ledger Gazette
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Marea Informative

Asset Management One Co. Ltd. Sells 235 Shares of Regeneron Pharmaceuticals Inc (REGN)
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Kiniksa Pharmaceuticals IPO: Cash KingSeeking Alpha

all 129 news articles »

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central ...

and more »

Take eye 'blackouts' seriously, doctor urges
Taipei Times
Two percent of people over the age of 40 suffer from various degrees of branch or central retinal vein occlusion and some have suffered an eye stroke because of dehydration, Hsu said. Strenuous exercise should be accompanied by ample rehydration, Hsu ...


StockNewsTimes

Rockefeller Capital Management LP Buys New Stake in Regeneron Pharmaceuticals Inc (REGN)
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Kiniksa Pharmaceuticals IPO: Cash KingSeeking Alpha
The Bull Case for Regeneron Pharmaceuticals Inc Couldn't Be More ClearYahoo Finance
StreetInsider.com
all 116 news articles »

Placenta Growth Factor Market Insights June 2018 covering Market Share, Market Concentration Rate, Mergers and ...
satPRnews (press release)
A new report titled Global Placenta Growth Factor Market Professional Survey Report 2018 has been added to the database of Trusted Business Insights (TBI). In this report the Placenta Growth Factor Market is valued (valuation provided in sample report) ...


The Ledger Gazette

State of New Jersey Common Pension Fund D Has $2.76 Million Holdings in Regeneron Pharmaceuticals Inc ...
The Ledger Gazette
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Global Placenta Growth Factor Market 2018: Research Analysis, Strategies, Business Plan, Revenue & forecast 2018 ...
faircolumnist.com
The Research report published by QuestForesight Global Placenta Growth Factor Market 2018 provides global coverage of Placenta Growth Factor market data from 2013 to 2018. The Placenta Growth Factor report begins with the overview of Placenta ...


StockNewsTimes

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Bought by Korea Investment CORP
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Macon Daily

Gabelli Funds LLC Acquires 800 Shares of Regeneron Pharmaceuticals Inc (REGN)
Macon Daily
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Medgadget (blog)

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion (RVO ...


Macon Daily

Regeneron Pharmaceuticals (REGN) PT Set at $290.00 by Barclays
Macon Daily
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Ostrum Asset Management Buys Shares of 314 Regeneron Pharmaceuticals Inc (REGN)
Enterprise Leader
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
... short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


MD Magazine

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure
MD Magazine
Eleven patients had at least an eye with branch retinal vein occlusion. Ten eyes had age-related macular degeneration (AMD), 7 had proliferative diabetic retinopathy, 6 had central retinal vein occlusion, 5 had central serous chorioretinopathy, and 3 ...


The Ledger Gazette

Somewhat Positive Press Coverage Somewhat Unlikely to Impact Regeneron (REGN) Stock Price
The Ledger Gazette
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Global Placenta Growth Factor Market Insights 2018 and Report covering Market Dynamics, Industry Size, Growth ...
satPRnews (press release)
A new report titled Global Placenta Growth Factor Market Research Report 2018 has been added to the database of Trusted Business Insights (TBI). In this report the Global Placenta Growth Factor Market is valued (valuation provided in sample report ...

and more »

Nasdaq

What's in the Offing for Regeneron (REGN) in Q1 Earnings?
Nasdaq
... neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and macular edema following branch retinal ...

and more »

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein ...
Digital Journal
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023. Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is ...

and more »

Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
The researchers further divided the RVO group into individuals with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Compared to people with neither form of RVO, the adjusted hazard ratios for CRVO and BRVO were 1.35 and ...

» Load more